TW202103709A - 用於治療患有慢性腎臟病之對象的方法 - Google Patents

用於治療患有慢性腎臟病之對象的方法 Download PDF

Info

Publication number
TW202103709A
TW202103709A TW109109737A TW109109737A TW202103709A TW 202103709 A TW202103709 A TW 202103709A TW 109109737 A TW109109737 A TW 109109737A TW 109109737 A TW109109737 A TW 109109737A TW 202103709 A TW202103709 A TW 202103709A
Authority
TW
Taiwan
Prior art keywords
canagliflozin
patient
drug
kidney disease
chronic kidney
Prior art date
Application number
TW109109737A
Other languages
English (en)
Chinese (zh)
Inventor
諾曼 羅森塔爾
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202103709A publication Critical patent/TW202103709A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW109109737A 2019-03-26 2020-03-24 用於治療患有慢性腎臟病之對象的方法 TW202103709A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962823719P 2019-03-26 2019-03-26
US201962823724P 2019-03-26 2019-03-26
US201962823722P 2019-03-26 2019-03-26
US62/823,724 2019-03-26
US62/823,719 2019-03-26
US62/823,722 2019-03-26
US201962835550P 2019-04-18 2019-04-18
US62/835,550 2019-04-18

Publications (1)

Publication Number Publication Date
TW202103709A true TW202103709A (zh) 2021-02-01

Family

ID=70050106

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109109737A TW202103709A (zh) 2019-03-26 2020-03-24 用於治療患有慢性腎臟病之對象的方法

Country Status (8)

Country Link
US (1) US20220160739A1 (https=)
EP (1) EP3946367A1 (https=)
JP (2) JP2022526914A (https=)
CN (1) CN113613659A (https=)
CA (1) CA3134786A1 (https=)
MX (1) MX2021011711A (https=)
TW (1) TW202103709A (https=)
WO (1) WO2020193652A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216870A1 (en) * 2021-04-07 2022-10-13 Ur-1 Therapeutics, Inc. Urat1 inhibitor, pharmaceutical compositions and uses thereof
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders

Also Published As

Publication number Publication date
JP2025111453A (ja) 2025-07-30
EP3946367A1 (en) 2022-02-09
WO2020193652A1 (en) 2020-10-01
JP2022526914A (ja) 2022-05-27
CN113613659A (zh) 2021-11-05
US20220160739A1 (en) 2022-05-26
MX2021011711A (es) 2021-10-22
CA3134786A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
Baker et al. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension
CA2907079C (en) Combination of canagliflozin and probenecid for the treatment of hyperuricemia
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
JP2016528303A (ja) 新規使用
JP2025111453A (ja) 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
WO2012171015A2 (en) Therapeutic combination for cancer treatment
US20190307791A1 (en) Use of ferric citrate in the treatment of and the reduction of mortality and morbidity related to adverse cardiac events in chronic kidney disease patients
EP2891499A1 (en) Combination of sglt2 inhibitor and anti-hypertension drug
CN118401241A (zh) 用于治疗慢性肾脏病的醛固酮合成酶抑制剂
Theriot et al. Antiemetics, selective 5-HT3 antagonists
TW202038937A (zh) 治療高血壓的方法
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
CN103417971A (zh) 二肽基肽酶抑制剂和b族维生素的药物组合物及用途
JP7569492B2 (ja) 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
CN101229372A (zh) 一种治疗高血压的药物组合物
EA047563B1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
JP2005531492A (ja) 高リスク患者のｉｉ型糖尿病を低減させる方法
HK40062581A (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
CN113876766B (zh) 一种阿利沙坦酯吲达帕胺复方药物组合物的新应用
CN101596195B (zh) 降低血压的口服药物组合物
TW200403054A (en) Drug composition for prevention or inhibition of advance of diabetic complication
Kavanagh Antihypertensive drugs
Tablets et al. Pr SANDOZ SAXAGLIPTIN
TW201103544A (en) Pharmaceutical composition and application thereof
Snyder Nausea, Vomiting, and Hyperemesis of Pregnancy